ADME-toxicology testing market driven by the increasing efforts to reduce drug development costs

Press Release   •   Dec 12, 2013 10:15 GMT

The ADME-Toxicology Testing market has been forecast to reach a value of $10.1 billion by 2018, driven by the growing emphasis on Toxicology Testing in early stages of drug development, and increasing efforts to reduce drug development costs.

ADME is an abbreviation in pharmacokinetics and pharmacology for absorption, distribution, metabolism, and excretion, and describes the disposition of a pharmaceutical compound within an organism.

The four criteria all influence the drug levels and kinetics of drug exposure to the tissues and hence influence the performance and pharmacological activity of the compound as a drug.

ADME-toxicology testing is gaining significance in drug development. New drug discovery is a high risk, high cost proposition for pharmaceutical and biotech companies particularly due to the high attrition rate at every stage of drug development.

The traditional drug development model inculcated toxicity and efficacy testing in in-vivo models, while ADME was used during compound selection.

With time, however, the industry began to gain better understanding of the importance of structure-activity relationship in the design of new drugs, which led to improved focus on toxicology testing.

A key reason attributed to late stage drug failures is the inability of drug candidates to mimic safety profiles witnessed in animal models in humans. Pharmaceutical companies are therefore focusing on incorporating toxicology testing in early drug development stages.

Due to synthesis of a large number of new molecules over the past few years, there has been an increase in the number of potential lead compounds, which is resulting in an increase in ADME-Tox screening.

Advancements in ADME-Tox technology in terms of enhanced accuracy and predictability is expected to provide significant impetus to the market, as the industry moves towards ADME-Tox screening at early stages of drug development in order to reduce drug attrition rate at later stages.

According to a recent market report, 'ADME-Toxicology Testing: A Global Strategic Business Report,' the United States represents the largest market worldwide, while Asia-Pacific is forecast to emerge as the fastest growing market, experiencing a compoundannual growth rate of 22.9% over the next five years.

Growth in the region is led by government support and increasing number of collaborations between foreign pharmaceutical companies and research laboratories.

For more information on the ADME-toxicology testing market, see the latest research: ADME-Toxicology Testing Market

Follow us on Twitter @CandMResearch issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.